HARMONY Alliance Foundation at ELN Symposyum

We will participate in the 21st Symposium of ELN, European LeukemiaNet, organized in the Congress Center Rosengarten, Mannheim, Germany on 25 February.he Agenda for the program can be downloaded here.

Many of the researchers involved in HARMONY Alliance Research Projects will participate and present progress and results from ongoing activities. The agenda for the meeting will be as follows:

11:30   Welcome. Overview of main achievements in 2024, by Jesús Hernández

11:45   Results from ongoing research projects, chaired by Lars Bullinger

• Jesse Tettero: Measurable Residual Disease as surrogate endpoint for survival in AML: A HARMONY project

• Lars Bullinger on behalf of Rabea Mecklenbrauck: The prognostic impact of myelodysplasia-related gene mutations in AML with FLT3-ITD mutations

• Amin Turki: Fully unsupervised genomic classification of patients with diagnosed AML via two distinct Hierarchical Dirichlet Mixture models using the HARMONY Platform

•Amin Turki on behalf of Marta Sobas: Outcomes with intensive treatment for acute myeloid leukemia over two decades on behalf of M Sobas

• Luca Guarnera: Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL || APL-like AML: clinical phenotype, biological background and future perspectives

• Amir Enshaei: Introducing the HARMONY Advanced ALL Analysis Dashboard

• Thomas Ernst: iCMLf Genomics Project update     

12:45   Roadmap for 2025, by Jesús Hernández

 

We are looking forward to reconnecting with our peers representing the various research areas in hematology. The HARMONY Alliance Foundation would like to thank ELN for this opportunity.

 

 

---

Receive the latest news. Click here to subscribe!